
    
      Patients with high-risk, locally advanced (TxN2b~3 or T4N0~3, M0) OSCC will be eligible. To
      detect an interested objective response rate (p1) of 80% versus a non-interested response
      (p0) rate of 60%, with an α and 1-β of 0.05 and 0.2, respectively (two-sided test), including
      the estimated dropout rate of 10%, a total of 47 patients will be recruited.
    
  